Dr. Ramsey’s talk went into detail about how the CFF is working to “leave no mutation behind.” She talked about what was learned in the process of getting a successful FDA approval for Kalydeco and how we can use that “roadmap” to guide us toward successful treatments for other mutation classes. I mentioned in the day 1 summary that knowledge of your personal mutations and their functional class will be crucial to take advantage of genetic modifying treatments like Kalydeco. In the spirit of discovery, it is important to mention that the CFF has a free program to identify unknown mutations in patients called MAP—The Mutation Analysis Program. If you have a CF diagnosis, but only 1 known mutation, the CFF will sequence your genome for free and find it! This is so incredibly important. Standard panels to screen for CF usually include the most common 23-26 mutations. NONE OF THE OTHER GATING MUTATIONS (other than G551D) ARE INCLUDED IN THE SCREENING PANELS! If you still have an unknown mutation, it could potentially be in the gating class, and Vertex has already applied to the FDA to expand Kalydeco access to these patients! Imagine what a pleasant surprise it would be to learn that your rare unknown mutation has a gating defect and you could soon begin taking and benefiting from Kalydeco!!! I hope everyone with an unknown mutation will take advantage of this. http://www.cff.org/LivingWithCF/AssistanceResources/MAP/ If you know your mutations, but are unsure of which class they fall into, you may find that information on http://cftr2.org/. Another valuable explanation of mutation classes and their dysfunction can be found at http://www.cftrscience.com/ I wrote a blog in 2011 about mutation classes: http://luckycfmom.blogspot.com/2011/11/mutation-matters.html Of course, the CF clinic team may also be able to offer information on this as well.